RCS - N4 Pharma PLC - N4 Pharma CEO Q&A Now LIVE

N4 PharmaAnnouncement

01/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241101:nRSA4862Ka&default-theme=true

RNS Number : 4862K  N4 Pharma PLC  01 November 2024

 

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

N4 Pharma CEO Q&A Now LIVE

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, is
pleased to announce the release of an investor Q&A from CEO, Nigel
Theobald.

 

Investors were invited to submit questions on the October 2024 New Corporate
Presentation (https://investors.n4pharma.com/announcements/6594619) , full
slide deck here
(https://investors.n4pharma.com/activity-updates/n4-pharma-corporate-presentation-october-2024)
.

 

The Q&A response is now live on N4 Pharma's interactive investor hub here:
https://investors.n4pharma.com/link/0y5jle
(https://investors.n4pharma.com/link/0y5jle) .

 

Any additional follow up questions from investors will be answered by CEO
Nigel Theobald in the coming days via the hub.

 

 

 

For more information please contact:

 

 N4 Pharma plc                                                Via IFC Advisory

 Nigel Theobald, CEO

 Luke Cairns, Executive Director
 SP Angel Corporate Finance LLP                               Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                        Tel: +44(0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope
 IFC Advisory Ltd                                             Tel: +44(0)20 3934 6630

 Financial PR

 Graham Herring

 Zach Cohen
 InvestorHub                                                  Sign up at investors.n4pharma.com (http://investors.n4pharma.com)

 Engage with us directly at N4 Pharma Investor Hub

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel
antigens in these fields to use Nuvec® as the delivery vehicle for these
antigens. As these products progress through pre‐clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at
https://investors.n4pharma.com/auth/signup
(https://investors.n4pharma.com/auth/signup) .

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAXEFDFELFFA